Assembly Biosciences (NASDAQ:ASMB) Earns Neutral Rating from HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. HC Wainwright also issued estimates for Assembly Biosciences’ FY2029 earnings at ($12.58) EPS.

Assembly Biosciences Stock Up 2.7 %

Shares of ASMB stock opened at $11.42 on Monday. The business has a fifty day simple moving average of $12.77 and a 200 day simple moving average of $15.05. The company has a market cap of $72.59 million, a P/E ratio of -1.70 and a beta of 0.62. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The firm had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.05 million. As a group, equities research analysts anticipate that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton acquired 3,202 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the purchase, the director now directly owns 3,202 shares of the company’s stock, valued at $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors have recently added to or reduced their stakes in ASMB. Gilead Sciences Inc. acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $34,865,000. Renaissance Technologies LLC lifted its position in shares of Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock valued at $1,495,000 after acquiring an additional 29,087 shares during the period. Peapod Lane Capital LLC bought a new position in Assembly Biosciences during the fourth quarter worth $994,000. B Group Inc. acquired a new stake in Assembly Biosciences in the fourth quarter worth $799,000. Finally, Monimus Capital Management LP bought a new stake in Assembly Biosciences in the fourth quarter valued at $664,000. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.